Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS will soon commercialize biosimilar medicines, starting with Humira. The move will likely drive a faster pace of growth, but not by a huge amount.

CVS Just Made a Major New Announcement, But Should You Buy It?

WOONSOCKET, R.I. , Aug. 31, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that President and CEO Karen S.

CVS Health to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

WOONSOCKET, R.I. , Aug. 29, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) is actively preparing for Hurricane Idalia's impending landfall along Florida's Gulf Coast.

CVS Health supporting customers, patients, members and colleagues as Hurricane Idalia approaches

AbbVie

Enphase Energy

Intel

NIKE

Paramount Global

Taiwan Semiconductor Manufacturing

Financial opportunities are as abundant as they are volatile. Seizing a selected group of blue-chip stocks to buy could lead to unparalleled investor growth.

Now or Never: 7 Blue-Chip Stocks Offering a Once-in-a-Lifetime Opportunity

CVS Health's (CVS) wholly owned subsidiary, Cordavis, is set to bring high-quality biosimilar products to the market.

CVS Health's (CVS) Cordavis to Focus on Biosimilar Products

CVS Health is coming off a tough quarter with multiple segments reporting lower earnings. It incurred $496 million in restructuring costs as a result of acquisitions and operations streamlining.

CVS Health's Earnings Crashed 37% in Q2: Should Investors Be Worried?

AT&T

CVS Health stock recently tanked in response to what could be a relatively minor loss of business. AT&T offers a big 7.8% yield at recent prices, and steadily growing subscription revenue could allow it to maintain and raise its dividend in the years ahead.

2 Beaten-Down Dividend Stocks That Look Like Bargains Now

CVS Health Corp. CVS, -0.97% said Wednesday that it has launched a new subsidiary that will work directly with drugmakers to co-produce and commercialize biosimilars. The subsidiary, Cordavis, has contracted with Novartis AG's NVS, +0.23% Sandoz unit to commercialize a biosimilar for AbbVie Inc.'s ABBV, -0.78% Humira, CVS said in a release.

CVS Health launches biosimilars subsidiary, will commercialize Humira competitor

CVS Health Corp said on Wednesday it has launched Cordavis, a unit that will work directly with manufacturers to commercialize and co-produce biosimilars for the U.S. market.

CVS launches unit to market and co-produce biosimilars

CVS Health is launching a new company, Cordavis, to commercialize and produce biosimilar drugs, the cheaper versions of expensive prescriptions derived from biotechnology.

CVS Health Launches Company To Produce Cheaper ‘Biosimilar' Versions Of Expensive Biotech Drugs

CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.

CVS pushes further into generic drugs with Sandoz partnership for new discount Humira

New business will bring high quality biosimilar products to market with goal of reducing drug spend and ensuring access to affordable medications Cordavis to launch biosimilar Hyrimoz® with Sandoz beginning in 2024 at more than 80% lower list price than Humira ®* WOONSOCKET, R.I. , Aug. 23, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that it has launched Cordavis, a wholly owned subsidiary that will work directly with manufacturers to commercialize and/or co-produce biosimilar products (an FDA approved biologic medication that is highly similar to, and has no clinically meaningful differences from, a biologic medicine already approved by the FDA) for the U.S. pharmaceutical market.

CVS Health Launches Cordavis

Quest Diagnostics

Pfizer

Covid-19 related stocks started spiking again this week. Driven primarily by reports about new variants and increasing spread.

3 Pharma Stocks to Buy as Summer COVID Cases Spike

Chevron

Toyota Motor

Navigating the stock market is a journey mixed with analysis, timing, and good fortune. But for those looking at wealth accumulation, there's always the burning question: which are the stocks to buy to get rich?

Want to Get Rich? 3 Game-Changing Stocks to Buy Right Now

Shares of retail pharmacy chain CVS Health (NYSE: CVS ) only managed modest gains during Friday's afternoon session, an unremarkable consolation following yesterday's dramatic implosion. Sparking the downside was insurer Blue Shield of California, which disclosed that it would reduce reliance on CVS' pharmacy business.

CVS Stock Price Predictions: What to Know as Analysts Cut CVS Price Targets

CVS stock is down close to 30% this year, and I believe it might be a steal for dividend investors.

Is CVS Stock a Buy After the Recent Drop?

Blue Shield of California's decision not to use the PBM, which negotiates prices on behalf of insurers, is a setback for CVS and a risk for other PBMs.

CVS Sees Stock-Price Targets Cut. It Could Still Be a Buy.

CVS Caremark will provide Blue Shield of California members "specialty pharmacy services for members with complex conditions, including education and high-touch patient support.”

CVS Retains Blue Plan's Specialty Pharmacy Business And That's Where The Money And Costs Are

CVS Health Corp. CVS, -8.13% expects a major health insurer's decision to reduce its reliance on CVS Caremark pharmacy benefit manager services will have “an immaterial impact on our longer-term outlook” and no impact on 2023 guidance, the company said in a statement Thursday. Blue Shield of California, a nonprofit health plan, said earlier Thursday that it would work with several new organizations as part of an overhaul of its prescription-drug benefit strategy but retain CVS Caremark for specialty pharmacy services for members with complex conditions.

CVS Health says loss of Blue Shield business has no significant impact on longer-term outlook, stock down 8%

CVS Health Corp (NYSE:CVS) is down 8.7% to trade at $66.43 at last check, after news that Blue Shield of California is dropping the retailer's pharmacy services in favor of Mark Cuban's Cost Plus Drugs and Amazon Pharmacy.

CVS Stock Hits 2-Year Low After Blue Shield Snub

Blue Shield of California plans on trimming its partnership with CVS Health Corp (NYSE: CVS) to cut costs. Shares of the healthcare company are down 8.0% on Thursday.

Blue Shield of California to trim its partnership with CVS Health

Amazon

Blue Shield of California will end its CVS Health prescription benefit management contract and tap Amazon to replace it.

CVS Health Dives As Blue Shield Of California Taps Mark Cuban, Amazon In Challenge To PBM Model

Is Blue Shield of California dumping CVS Health in favor of Amazon.com to manage its pharmacy benefits? Yes and no.

Why CVS Health Stock Crashed 11 Percent Today

Blue Shield's announcement hints at the potential for health insurers to abandon the traditional PBM system.

CVS stock plunges after Blue Shield of California drops company's PBM to save on drug costs

CVS Health (NYSE: CVS ) stock is taking a beating on Thursday after health insurance company Blue Shield revealed plans to switch away from its pharmacies. Blue Shield, which is a non-profit health insurer, is mostly dropping CVS Health as its preferred pharmacy in California.

News for CVS Health Stock (CVS)